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Sublobar Resection
A Movement from the Lung Cancer Study Group
Justin D. Blasberg, MD,* Harvey I. Pass, MD,†‡¶ and Jessica S. Donington, MD†¶
Abstract: The 1995 Lung Cancer Study Group consensus recom-
mending lobectomy for stage I non-small cell lung cancer (NSCLC)
has directed lung cancer resections since its publication. However,
enhancements in imaging technology over the last decade have
produced larger cohorts of patients presenting with localized, early-
stage disease. Today, multislice computer tomography is widely
available, capable of detecting NSCLC at smaller sizes, with im-
proved spatial resolution, and is used in screening programs for
high-risk individuals. Furthermore, the maturation of minimally
invasive surgical resection (video-assisted thoracoscopic surgery)
has reduced perioperative morbidity and mortality, improved post-
operative lung function, and demonstrated equivalent oncologic
effectiveness to open surgery. The mandatory use of lobectomy for
patients with small stage IA NSCLC is now being challenged.
Numerous single-institution trials have demonstrated that well-
selected use of sublobar resection can afford comparable survival
and recurrence rates to lobectomy, particularly in high-risk patients.
Currently, a prospective, randomized multi-institutional phase III
trial is being conducted by the Cancer and Lymphoma Group B
(CALGB 140503) to determine whether patients with small (2 cm)
peripheral NSCLC tumors can safely undergo sublobar resection
while maintaining rates of survival and recurrence that are compa-
rable to lobectomy. This review summarizes the literature from the
past 15 years to assist in applying those conclusions to future
research innovation.
Key Words: Non-small cell lung cancer, Surgery, Lobectomy,
Sublobar resection, Segmentectomy, Wedge resection.
(J Thorac Oncol. 2010;5: 1583–1593)
The 1995 publication from the Lung Cancer StudyGroup’s (LCSG) prospective randomized trial of lobec-
tomy versus limited resection for stage IA non-small cell
lung cancer (NSCLC) reinforced the need for formal
lobectomy in early-stage patients. Demonstrating an in-
creased risk for local/regional recurrence, reduced 5-year
mortality, and no statistical evidence for preservation of
pulmonary function, this study disproved speculation that
sublobar resection had comparable outcome to lobect-
omy.1,2 Since that time, the utility of spiral computer
tomography (CT) imaging has refined the presentation and
diagnosis of early-stage NSCLC.3,4 Improved spatial res-
olution, detection of ground glass opacities (GGOs) asso-
ciated with favorable histology, and increased screening of
high-risk individuals has created a growing cohort of
patients with smaller tumors than those assessed in the
LCSG trial. Concurrent improvements in adjuvant chemo-
therapy and radiation therapy techniques, as well as a
growing population of older patients with significant med-
ical comorbidities that preclude larger operations, have
further driven research to determine the effectiveness of
limited resection.
Theoretical advantages of sublobar resection include
preservation of pulmonary function, improved periopera-
tive morbidity and mortality, and increased potential for a
second resection with a subsequent primary tumor.1,5–10
Multiple single-institution studies have demonstrated
equivalent rates of survival and recurrence for patients
with small, early-stage tumors that lack gross evidence of
lymph node involvement. Increased utilization of minimal
access surgical techniques in conjunction with innovation
in adjuvant therapy, including the application of brachy-
therapy, are recent improvements that strengthen the like-
lihood of sublobar resection affording equivalent survival
and rates of recurrence compared with lobectomy. This
review of the literature from the last 15 years serves to
summarize the clinical research investigating the use sub-
lobar resection in early-stage NSCLC. We will focus on
the importance of tumor size, extent of resection (wedge
resection versus segmentectomy), adequate surgical mar-
gins, bronchioloalveolar histology, and adjuvant brachy-
therapy on freedom from recurrence and survival.
HISTORY
Considerable interest in sublobar resection arose in
the 1970s and 1980s when the international community
demonstrated the feasibility of limited resection for pa-
tients with compromised cardiopulmonary reserve.11 At
that time, 5-year survival data and recurrence rates were
deemed inferior to lobectomy, and sublobar resection was
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restricted to patients with impaired cardiac function or
significant comorbidities precluding conventional lobec-
tomy. Early work by Warren and Faber12 in 173 patients
with stage I NSCLC demonstrated decreased survival and
increased recurrence for sublobar resection versus lobec-
tomy. Continued speculation about the prospects of limited
resection prompted the large prospective randomized
LCSG trial in 247 patients with stage IA NSCLC compar-
ing limited resection with lobectomy. This study demon-
strated a 39% increase in local recurrence and a nonsig-
nificant decrease in overall survival after sublobar
resection.1,2 It included patients with tumors up to 3 cm
and a significant number of nonanatomic wedge resections
(1 of 3 sublobar procedures). In retrospect, both these
parameters may have significantly limited the effective-
ness of sublobar resection.1 Shortly after the LCSG, inves-
tigators from the University of Pittsburgh published a
prospective, multicenter, nonrandomized study that dem-
onstrated equivalent 1-year survival and 5-year actual
survival favoring lobectomy (70% versus 58%). The in-
creased rate of death after limited resection was due almost
entirely to non-lung cancer causes (38% versus 18% after
lobectomy) and was attributed to poor cardiopulmonary
reserve in that cohort. Higher rates of local/regional recur-
rence after sublobar resection were also demonstrated
(18% versus 4%).13
Since these landmark publications, numerous single-
institution reviews have recapitulated these results, dem-
onstrating an overall survival advantage for lobectomy.
Sienel et al.14 established poorer cancer-related 5-year
survival and increased local/regional recurrence after seg-
mental resection compared with lobectomy for stage IA
cancer (16% versus 5%), attributing worse outcome to
tumor size and width of resection margin. Kraev et al.15
demonstrated that lobectomy for stage IA tumors had
significantly better 10-year survival than wedge resection,
recognizing size as an important prognostic variable to
consider when planning sublobar resection. A review by
Chang et al.16 of data from the Surveillance, Epidemiol-
ogy, and End Result Program (SEER) also demonstrated
inferior survival with sublobar resection compared with
lobectomy (44% versus 61%) for stage IA disease. Limited
resection was associated with fewer dissected mediastinal
lymph nodes, reinforcing the importance of lymph node
assessment in staging and prognosis. Risk for recurrence in
these evaluations was independent of histology.
Recent single-institution retrospective investigations
evaluating the equivalency of sublobar resection to lobec-
tomy in patients with limited cardiopulmonary reserve
contradict earlier results and have demonstrated that stage
I disease portends a survival advantage regardless of the
extent of surgical resection or histologic subtype (Table 1).
The majority of these studies assessed patients preopera-
tively by CT alone, without mediastinoscopy or positron
emission tomography (PET), and performed anatomic seg-
mentectomy with intraoperative mediastinal lymph sampling
or dissection and demonstrated comparable 5-year survival
between lobectomy and sublobar resection. Campione et TA
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al.17 found no significant difference in survival between
lobectomy and anatomic segmentectomy in a series of 121
stage IA patients (median survival: 98 months for lobec-
tomy versus 104 months for sublobar resection). Martin-
Ucar et al.18 retrospectively matched 17 stage IA lobec-
tomy patients to an equal number of segmentectomy
patients based on age, gender, use of video-assisted tho-
racoscopic surgery (VATS), tumor location, and respira-
tory function and found no difference in morbidity, mor-
tality, 5-year survival, or recurrence. The group from the
University of Pittsburgh retrospectively assessed outcomes
in 784 stage IA patients and found equivalent disease-free
survival and rates of recurrence regardless of resection
technique; average tumor size in their sublobar cohort was
1.8 cm, stressing the importance tumor size as a prognostic
variable.19 In a subsequent analysis of 184 patients with
stage I NSCLC older than 75 years, the Pittsburgh group
demonstrated that segmentectomy was associated with
fewer perioperative complications, similar length of hos-
pitalization, and equivalent overall and 5-year disease-free
survival compared with lobectomy, even when used in a
medically compromised population.6
These studies and others have outlined specific prog-
nostic factors that play an important role in determining
survival and recurrence after sublobar resection: (1) tumor
size, (2) lymph node assessment, (3) anatomic versus
nonanatomic resection techniques, and (4) adequate surgi-
cal margins. These parameters, in addition to the growing
body of work from Japan highlighting the utility of sub-
lobar resection for bronchioloalveolar carcinoma (BAC),
have become the focus of investigation into the appropriate
use of limited resection for NSCLC.6,20,21
TUMOR SIZE
Warren’s 1994 series provided early evidence that
tumor size carried important prognostic relevance, with a
distinct survival advantage and decreased rates of recur-
rence for tumors less than 2 cm.12 These results have been
replicated by multiple large surgical series including two
independent reviews of the SEER database by Chang et al.
and Mery et al.16,22 Each found a significant survival
improvement for stage IA tumors more than 2 cm com-
pared with those 2 to 3 cm in size. Approximately 25% of
patients with tumors less than 2 cm were successfully
treated by limited resection in these reviews.16,23 Port et
al.24 and Birim et al.5 also reported improved survival and
local control in resected stage IA tumors less than 2 cm
compared with those 2 to 3 cm in size.
Several modern trials examining sublobar resection
have stratified tumors that are larger and smaller than 2 cm
and demonstrate a reproducible difference in outcome
based on tumor size irrespective of gender, use of invasive
preoperative mediastinal staging, minimally invasive or
open surgical resection, or performance of segmentectomy
versus wedge (Table 2). Bando et al.,26,27 Fernando et al.,2
and Okada et al.28 each evaluated the impact of tumor size
less than 2 cm as an independent predictor of recurrence
and survival after sublobar resection. Although these three TA
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series contained a mixed population of healthy and medi-
cally compromised patients, a distinct survival advantage
for tumors less than 2 cm compared with tumors 2 to 3 cm
in size was demonstrated. A follow-up evaluation by
Bando et al. also investigated the impact of size on
survival and recurrence and correlated these findings with
the expression of specific tumor markers. Patients were at
significantly higher risk for local/regional recurrence after
resection of tumors 2 to 3 cm in size, particularly when a
concurrent increase in expression of carcinoembryonic
antigen, squamous cell carcinoma-related antigen, or frag-
ment of cytokeratin was demonstrated. For tumors less
than 2 cm without elevated tumor markers, no recurrence
was reported, and 5-year survival was 92%.27
The findings from these trials mirror data from the
recent lung cancer staging project headed by the Interna-
tional Association for the Study of Lung Cancer with
respect to the importance of stratifying tumors around a 2
cm cutoff. In this project, tumors less than 2 cm and those
2 to 3 cm were found to have statistically significant
differences in 5-year survival (77% versus 71%) and lead
to the reclassification of T1 tumors in the revised staging
system. In this revision, tumors less than 2 cm are denoted
as T1a and tumors between 2 and 3 cm as T1b.29
Tumor size is an important independent predictor of
outcome in NSCLC. Although the LCSG alluded to a sur-
vival advantage based on tumor size, more recent literature
has successfully characterized tumors less than 2 cm as a
distinct entity with improved outcome and may represent the
population in whom sublobar resection should be contem-
plated and the equivalency of resection evaluated. This is
particularly relevant to patients with BAC and will be dis-
cussed further.
SEGMENTECTOMY VERSUS WEDGE
RESECTION
Although imaging refinements have revolutionized
our ability to diagnose early-stage NSCLC, surgical tech-
nology has also advanced with improvements in the oper-
ative techniques available for limited resection in medi-
cally compromised patients. VATS, which was not
practiced during the era of the LCSG trial, is now widely
performed. Equivalent long-term survival for VATS and
open surgical resection for NSCLC have been validated
specifically for stage IA disease (2 cm tumors), as have
the advantages of reduced blood loss, faster recovery,
preserved pulmonary function, and shorter hospitalization
for VATS.7,30 –32 Wedge resection by VATS is frequently
used in sublobar operations because of the technical ease
and favorable perioperative morbidity and mortality. Fre-
quently, patients presenting for limited resection have
coexisting cardiopulmonary impairment; wedge resection
by VATS in this setting is desirable because of reduced
operative times and reduced postoperative pain.10,21,33–35
However, overwhelming data suggest that nonana-
tomic wedge resections are an inferior oncologic approach
compared with anatomic segmentectomy. Higher recur-
rence rates associated with wedge resection are attributed
to important intralobar lymph node basins in the remaining
lung tissue.27 Anatomic segmentectomy has the theoretical
advantage of a more comprehensive resection, reduced
technical limitations for achieving appropriate margins,
and wider resection of draining lymphatics including in-
tersegmental planes commonly referenced as a source of
residual cancer cells.26,32 The dissection also allows en
bloc removal of adjacent anatomic segments based on
tumor size and invasion,27,32,36 which mirrors many of the
important characteristics of lobectomy.6,36 Newer tech-
niques, such as jet ventilation of individual segments,
further enhances identification of intersegmental planes.37
Separating data on anatomic segmentectomy from
nonanatomic wedge resection and analyzing the survival
and recurrence rates for each procedure is important when
evaluating sublobar resection for NSCLC. Yoshikawa et
al.38 demonstrated equivalent 5-year survival (82%) for
extended open segmentectomy and mediastinal lymph
node dissection as an intentional resection protocol for
patients with tumors less than 2 cm to historical controls
for lobectomy. Studies that report the results of wedge
versus segmentectomy independently are outlined in Table
3. In each, patients were staged preoperatively by CT scan
and underwent intraoperative mediastinal lymph node
sampling or dissection to properly identify involved lymph
node basins (N2).
A study by Miller et al. from the Mayo Clinic
specifically examining outcomes in tumors 1 cm ana-
lyzed outcome differences among lobectomy, segmentec-
tomy, and wedge. Although there was a distinct survival
advantage favoring lobectomy, subdivision of limited re-
section patients uncovered a statistically significant sur-
vival advantage and improved local control with segmen-
tectomy compared with wedge resection even in these very
small tumors.39 Okada et al.28 and El-Sherif et al.40 each
reported a critical difference in recurrence based on the
extent of resection in large retrospective reviews. In-
creased local/regional recurrence after wedge resection
was attributed to the technical limitations of achieving an
appropriate margin and incomplete dissection of intrapa-
renchymal and hilar lymph nodes with wedge.
In a review from Europe of sublobar resection in
stage IA patients with cardiopulmonary insufficiency,
Sienel et al. also found significantly less local/regional
recurrence (55% versus 16%) and improved cancer-spe-
cific survival (71% versus 48%) after anatomic segmen-
tectomy with systematic nodal dissection compared with
wedge resection with selective nodal sampling. In their
multivariate analysis, the type of resection, tumor size, and
age were significant prognostic indicators.41
VATS segmentectomy, similar to VATS lobectomy,
is now more widely performed but requires longer opera-
tive time and greater technical expertise compared with
open procedures.30 Experience with VATS segmentectomy
continues to expand in some series, demonstrating equiv-
alent oncologic effectiveness to VATS lobectomy. In a
recent assessment by Shapiro et al. specifically comparing
the equivalency of VATS segmentectomy for compro-
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mised patients to VATS lobectomy for tumors less than 3
cm, the number of resected lymph nodes, chest tube
duration, complications, recurrence rates (17.6% versus
16.7%), and overall 2-year survival were similar between
modalities. Mean tumor size was less than 2 cm for both
groups.10
The survival advantage and decreased rates of local/
regional recurrence after segmentectomy demonstrated in
these series are likely related to three key features inherent
to the technique: (1) resection along anatomic planes, (2)
wider resection margins, and (3) resection of intraparen-
chymal draining lymphatics. Primary sources of local
recurrence after NSCLC resection include remnant tumors
of intrapulmonary metastasis, intralobar lymph node me-
tastasis, and an incomplete resection with positive mar-
gins.26,42 Anatomic segmentectomy is regarded as an on-
cologically superior procedure compared with wedge
resection because it more definitively addresses these tu-
mor basins. However, regardless of the extent of resection,
thorough mediastinal lymph node assessment is suggested
for completeness of staging and to appropriately compare
outcome data with lobectomy.6,8,10,37
BRONCHIOLOALVEOLAR CARCINOMA
BAC is a noninvasive variant of adenocarcinoma
with unique clinical and radiologic features that distin-
guish it from other forms of NSCLC. It is reported in up to
24% of pathology specimens after resection of lung tumors
less than 2 cm. The incidence of BAC has increased
substantially over the past 20 years following the World
Health Organization reclassification to include tumors with
pure lepidic spread and no evidence of stromal, vascular,
or pleural invasion.43 A survival advantage conferred by
BAC was initially characterized in the United States after
an evaluation by the LCSG of 1635 patients with resected
adenocarcinomas less than 3 cm. A total of 235 specimens
demonstrated pure BAC histology, which correlated with
better overall survival and decreased risk for recurrence
compared with the invasive adenocarcinoma cohort. Ad-
ditional studies, including a Japanese review of 236 pa-
tients with peripheral adenocarcinomas less than 2 cm,
demonstrated that tumor histology with minimal stromal
response and no invasion (Noguchi type A or B) was
associated with 100% 5-year survival.44
The use of limited resection for patients with pure or
mixed BAC has been assessed in a variety of retrospective
Japanese trials (Table 4). In each of these studies, patients
with BAC had prolonged survival and lower recurrence
after resection than those with other subtypes of
NSCLC.45,46 Reviews by Yamada and Kohno and Yamato
et al.,45,47 using intentional limited resection in patients
with pure ground glass opacities (GGOs) less than 2 to 3
cm, demonstrated 100% survival and no evidence of re-
currence at median follow-up of 30 months. In another
assessment of long-term recurrence and survival by Wa-
tanabe et al., patients with suspected BAC underwent
intentional wedge resection with intraoperative pathologic
evaluation. No recurrence and 100% survival at 5 yearsTA
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was seen in patients with confirmed BAC histology on
intraoperative pathologic analysis, despite the fact that
intraoperative lymph node evaluation was not per-
formed.48,49
Sugi et al. analyzed the utility of intentional VATS
sublobar resection compared with VATS lobectomy in 159
clinical stage IA patients from Japan. The extent of resec-
tion was based on tumor size, achievable resection mar-
gins, and ratio of GGO on preoperative imaging. VATS
wedge resection was used only for peripheral tumors less
than 1.5 cm with GGO ratio of more than 75%, indicating
a high likelihood of pure BAC histology. Five-year recur-
rence-free survival in this group was 100%. Central tumors
or those 1.5 to 2 cm in size with a high GGO ratio were
resected by VATS segmentectomy with mediastinal lymph
node sampling, with 5-year recurrence-free survival of
90.5%. The remaining patients, with tumors 2 to 3 cm or
low GGO ratio, underwent VATS lobectomy with 5-year
recurrence-free survival of 94.5%.50 There was no statis-
tical survival difference between the groups, highlighting
the importance of size, favorable CT appearance with high
GGO ratio, and adequate resection margins to achieve
oncologic equivalency between sublobar resection and
lobectomy.
Two similar series by Kodama et al. and Okada et al.
used the same principles of tumor size, GGO ratio, and
need for wide resection margins to determine the extent of
resection in patients with small (2 cm) peripheral tumors.
Each series reported equivalent survival and recurrence
rates among lobectomy, segmentectomy, and wedge when
utilizing this resection algorithm, recognizing high GGO
ratio as predictor of decreased recurrence after sublobar
resection.28,51
It is becoming apparent that pure GGOs on diagnos-
tic imaging represent BAC without areas of invasive ade-
nocarcinoma, whereas tumors with mixed ground glass and
solid appearance are likely mixtures of both BAC and
invasive adenocarcinoma.52 In addition, tumors less than 2
cm with greater than 50% density of GGOs are unlikely to
have N1 or N2 lymph node metastasis. Five-year survival
after limited resection in these tumors is approximately
100% with no incidence of recurrence.53 These patients
may ultimately prove to be the most appropriate candidates
for intentional limited resection.54 –57 However, extrapola-
tion of these results to the use of intentional sublobar
resection for larger tumors and those with less than 50%
GGO ratio remains unproven.45,58,59
THE ROLE OF ADEQUATE MARGINS
Cancer surgery demands specific universal standards
that are critical for survival and low recurrence rates. One
of the most important of these regards the role of adequate
resection. Inadequate resection margins have been attrib-
uted to recurrence in a multitude of solid tumors including
NSCLC. Technical limitations that preclude negative sur-
gical margins are a more challenging issue for sublobar
resection than conventional lobectomy. Reliance on intra-
operative frozen section has traditionally been the soleTA
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modality for assurance that negative margins were
achieved; however, these results can be flawed. Several
molecular techniques have been developed, which are
useful for intraoperative margin assessment. Higashiyama
et al.60 described a cytologic lavage of surgical staplers as
a more sensitive tool to uncover positive margins after
resection. Ten percent of patients with negative margins by
frozen section had positive cytology on stapler lavage for
malignancy. Sawabata et al. evaluated the use of glass
slide brushings of staple lines after resection to uncover
residual malignant cells. Those with residual disease de-
tected at the staple line had nearly a 50% increased risk of
local recurrence, whereas negative cytology nearly ex-
cluded recurrence.61 Masasyesva et al. found a strong
association between K-ras mutations sequenced from
DNA isolated at the tumor resection margin and recur-
rence. Sixty-seven percent of patients with K-ras muta-
tions at histologically negative resection margins devel-
oped local/regional recurrence, whereas a lack of K-ras
mutation was associated with 0% recurrence.62 These tech-
niques are useful adjuncts for establishing negative mar-
gins after limited resection.
Inadequate surgical margins portend a significantly
higher risk of local/regional recurrence regardless of the
type of resection. It is uncertain how significantly this
affects long-term survival in patients with limited cardio-
pulmonary reserve and high noncancer-specific mortality.
When sublobar resection is used in medically fit patients
who would otherwise tolerate conventional lobectomy,
increased local/regional recurrence rates are more likely to
affect long-term survival, enhancing the importance of
adequate surgical margins. There is growing evidence that
negative cytologic margins alone are not adequate to
reduce the risk of local recurrence in NSCLC, and that a
tumor margin of at least 2 cm may be needed. A review of
sublobar resection in 81 stage IA patients from the Uni-
versity of Pittsburgh reported recurrence in 15% of pa-
tients with margins less than 1 cm and only 8% of patients
with more than 1-cm margins.40 Two independent series
from Sawabata et al. and Schuchert et al. identified a
margin distance greater than 2 cm and greater than the
maximal tumor diameter as favorable indicators for de-
creased recurrence after sublobar resection.9,63
Much of the literature over the last 10 years supports
anatomic segmentectomy over wedge resection because it can
more effectively achieve the goal of 2-cm margins. Regard-
less of the procedure performed, achieving adequate margin
distance is extremely important when considering sublobar
resection, especially when used as an alternative to lobec-
tomy in a medically fit population.
ADJUVANT BRACHYTHERAPY
Inadequate surgical margins are strongly associated
with recurrence after sublobar resection. As such, unac-
ceptable levels of local/regional recurrence, as demon-
strated by the LCSG and others, have driven improvements
in localized adjuvant therapy. Iodine-125 (125I) brachy-
therapy seed placement is an ideal technology for sublobar
resection, specifically for compromised patients with lim-
ited cardiopulmonary reserve. Medically compromised pa-
tients undergoing limited resection often survive long
enough to be at risk for cancer recurrence. Implantation of
brachytherapy seeds at the time of resection allows for the
delivery of a concentrated dose of radiation to the resection
margin in a quick and precise manner with little exposure
to the surrounding lung.64 This technique is a significant
advancement over adjuvant external beam radiation used
in the 1980s and 1990s, both in its effectiveness and lack
of associated treatment morbidity.65
d’Amato et al.66 first reported on the feasibility of
intraoperative brachytherapy in 14 medically compromised
patients undergoing VATS sublobar resection, demonstrat-
ing no additional morbidity or mortality after seed place-
ment. Multiple small, prospective series have reported
favorable recurrence rates for sublobar resection with
brachytherapy in medically compromised cohorts (Table
5). In a prospective analysis of medically compromised
patients with stage I NSCLC, Lee et al. reported a 10.5%
local recurrence rate after wedge resection with brachy-
therapy and 77% 5-year cancer-specific survival for tumors
less than 3 cm, which was comparable with a matched
lobectomy cohort. In patients with tumors more than 3 cm,
local recurrence was higher and survival decreased com-
pared with patients undergoing lobectomy.67
A review by Santos et al. specifically compared
recurrence and survival between sublobar resection with
and without adjuvant brachytherapy in a series of 203
patients with poor cardiopulmonary reserve and stage I
NSCLC. Local recurrence was reduced from 18.6 to 2%
with the addition of brachytherapy. No difference in op-
erative mortality, distant recurrence, or 4-year overall
survival (60% versus 67%, respectively) was found. Fail-
ure to demonstrate an improvement in survival was likely
due to underlying medical comorbidities.68 Dosimetric
analysis of this population reported by Johnson et al.65
confirmed that 125I seeds resulted in limited radiation fields
at the resection margin while sparing surrounding normal
lung tissue and concluded that brachytherapy was superior
to external beam radiation on parameters of cardiac toxic-
ity, lung fibrosis, and loss of pulmonary function.
A multi-institutional series of sublobar resection by
Fernando et al. reported on a subgroup of 60 patients who
received 125I seeds to resected staple lines and compared
survival and local recurrence to 64 sublobar resection
patients without brachytherapy. The type of sublobar re-
section was not specified, but local recurrence was reduced
from 17.2 to 3.3% with the application of brachytherapy
seeds.69 Birdas et al. reviewed 167 patients with resected
stage IB NSCLC and found that sublobar resection with
125I brachytherapy to have local recurrence rates to the
equivalent of lobectomy (3.2 and 4.8%, respectively).
They also reported similar rates of disease-free and overall
survival, despite decreased preoperative cardiopulmonary
function in the sublobar resection group.70
Sublobar resection with brachytherapy for patients
with medical contraindications to lobectomy seems to be a
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reasonable alternative. An ongoing multicenter, phase II
trial sponsored by the American College of Surgeons
Oncology Group (ACOSOG Z4032) is prospectively eval-
uating the use of sublobar resection with adjuvant 125I
brachytherapy seed placement in high-risk patients with
stage IA NSCLC. Local recurrence and survival are the
primary end points. All patients in this study undergo
cytologic analysis to ensure negative margins. Survival
will be compared between patients with and without
brachytherapy and ultimately matched to historical lobec-
tomy outcome data for analysis.
INTENTIONAL SUBLOBAR RESECTION
It is incredibly important when evaluating survival
after sublobar resection to differentiate between those
resections performed in a compromised situation for a
medically unfit population and those performed intention-
ally in patients who would otherwise tolerate lobectomy.
Improved detection of small peripheral tumors and GGOs
associated with favorable histology has led to the increased
use of sublobar resection in many centers to include
patients with adequate physiologic reserve.4 Both Ameri-
can and Japanese series have demonstrated that small
BAC, which is identified preoperatively by high GGO
ratio, represents an entity with improved survival and
reduced rates of metastatic disease to lymph nodes.4,71,72
Additional parameters such as the absence of pleural
invasion,73 lack of spiculation,74 or lack of elevations of
tumor markers have also been shown to have prognostic
significance in early-stage NSCLC.27 Selection of medi-
cally fit patients with very favorable tumors for intentional
limited resection is gaining acceptance in the international
community.
An early nonrandomized Japanese trial from Kodama
et al. compared recurrence and survival in medically fit
patients with stage IA NSCLC undergoing “intentional”
segmentectomy with lymph node dissection to standard
lobectomy and to a small cohort of medically unfit patients
undergoing a “compromised” sublobar resection. Five-
year survival after intentional limited resection was 87%
and comparable with lobectomy at 86%. Local/regional
recurrence was also comparable with lobectomy at 4.3%.
The intentional sublobar group had improved overall and
cancer-specific survival and local/regional control com-
pared with the compromised group. Percentage of patients
in each group with BAC in this older series was not
reported, but results suggest that segmentectomy with
appropriate lymph node dissection may be a viable inten-
tional alternative for healthy patients with stage I disease,
especially for tumors less than 2 cm.74 Bando et al.,26,27
Koike et al.,75 and Okada et al.76 reported similar outcome
data for intentional sublobar resection in well-selected
patients with small peripheral NSCLC tumors. Each series
demonstrated equivalent local control and survival com-
pared with lobectomy (Table 6).
These studies establish the foundation for future
research that views sublobar resection as a means of
maintaining lung volume without an increased risk ofTA
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local/regional recurrence for selected patients with small
peripheral, early-stage NSCLC. Currently, a prospective,
randomized, multi-institutional phase III trial is being
conducted by the Cancer and Lymphoma Group B
(CALGB 140503) to determine the effectiveness of an
intentional sublobar resection protocol for small peripheral
tumors (2 cm). Conventional lobectomy is being com-
pared with sublobar resection (wedge or segmentectomy).
All patients will undergo intraoperative mediastinal lymph
node dissection to ensure negative involvement before
randomization.32 Results will likely provide important
contributions to the role of intentional resection for small,
peripheral stage IA tumors.
CONCLUSION
The future use of sublobar resection for NSCLC
needs to be founded on the long-standing principles of
surgical oncology, with selective use for small tumors and
those with favorable histologic profile, assurance of ade-
quate surgical margins, proper evaluation of hilar and
mediastinal lymph nodes, and the use of adjuvant therapy.
Each of these components has been independently associ-
ated with improved outcome. When selected appropriately,
early-stage patients, either healthy or with significant co-
morbidities, seem to have the potential for comparable
survival and recurrence to their lobectomy counterparts
with the thoughtful and appropriate use of sublobar resec-
tion. Patient and tumor characteristics and resection spec-
ifications that have been associated with improved survival
and reduced local recurrence after sublobar resection for
NSCLC are summarized in Table 7. Ultimately, the utility
of limited resection will be dependent on a system of
experienced thoracic surgeons, with an early detection/
screening protocol for high-risk individuals and a multi-
disciplinary approach to diagnosis, surgery, and adjuvant
therapy. Under those conditions, comparable survival is a
likely reality.
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